Skip to main content

Finvestedge Weekly Market Insights




v  Strides Pharma Science plans to acquire 18 new ANDAs from Pharmaceutics International Inc, which will significantly expand its fast-growing niche offerings. A big buy!

v  Going by its strong Q3 results, Apex Frozen Food is likely to post a robust FY20 performance. Its newly commissioned facilities will boost its performance further. Accumulate.

v  Britannia Industries posted 23% higher PAT for Q3 on the back of cost efficiencies. It has also cut trade inventory due to the slowdown. This evergreen FMCG share deserves a place in every portfolio.

v  Symphony posted an EPS of Rs.8 for Q3FY20 v/s Rs.6 in Q3FY19. Its 9MFY20 profit has already crossed the FY19 profit. Its future looks bright. Accumulate.

v  Alkem Laboratories’ Q3 profit nearly doubled to Rs.390 crore. With a hefty dividend of 1100%, this share merits a buy. Accumulate on dips.

v  Yet another good quarter for UPL with its highest-ever quarterly profit and an EPS of Rs.9 v/s Rs.6 last year. Buy for the long term.

v  Associated Alcohols & Breweries, the maker of Johnnie Walker whiskey, has been listed on the NSE. Its share price may rise with a rise in its volumes.

v  Besides posting fairly good results for Q3, Fermenta Biotech has declared a 2:1 bonus. A good time to buy.

v  RattanIndia Power, formerly Indiabulls Power, witnessed a significant turnaround in Q3. Its future looks bright. Accumulate.

v  The infrastructure industry is in for a big boost. It may be prudent to buy Welspun Enterprises.

v  Bliss GVS Pharma posted exciting results for Q3. This investor-friendly company is a good long-term bet.

v  The pick-up in steel demand followed by price hikes is likely to boost the share prices of Tata Steel and NMDC. Accumulate both.

v  Abbott India has begun its northward journey. There are rumours of a bonus, which is also reflected in its share price movement. Buy.

v  With the huge infra push from the government, efficient cement stocks like Ramco Cements and Shree Cement are likely to rise further.

v  Despite the 24% dip in Q3 PAT, Hindalco Industries remains a good investment bet. It is ramping up capacities to meet the anticipated rise in demand. Accumulate on dips.

v  The Balkrishna Industries counter has seen rising volumes and price volatility. At Rs.1157, it is an attractive buy.

v  Dr. Reddy’s Laboratories is on an expansion drive. It plans to acquire 62 domestic brands from Wockhardt for ~Rs.1850 crore. Buy for the long term.

v  Cochin Shipyard posted 33% higher PAT for Q3FY20. Going by its performance, it is likely to notch an EPS of Rs.50 for FY20. The stock is poised to touch Rs.500 on a reasonable P/E of 10x.

v  Going by its Q3 and 9MFY20 results, J.Kumar Infraprojects is likely to notch an EPS of Rs.30+ for FY20. Its future looks bright. Accumulate.

v  Hinduja Global Solutions may notch an EPS of Rs.90-100 for FY20 if its 9MFY20 results are taken into consideration. Its Q3 profit almost doubled to Rs.71.34 crore. Accumulate.

v  Going by its H1FY20 results, Kovai Medical Center & Hospital is expected to notch an EPS of Rs.75 for FY20. Buy for about 30% returns in the medium term.

v  Considering its 9MFY20 EPS of Rs.168, Vindhya Telelinks is likely to notch an EPS of Rs.230 for FY20. The stock trades at a P/E of just 3.6x and has the potential to double.

v  Going by its 9MFY20 results, Sasken Technologies is likely to notch an EPS of Rs.60 for FY20. The stock is poised to touch Rs.720 on a reasonable P/E of 12x.

Disclaimer:
This is strictly for informational purposes only. It is not a solicitation to buy, sell in securities or other financial instruments. FINVESTEDGE do not accept culpability for losses and/or damages arising based on information in this post. Contact your investment advisor before investing.

Comments

Popular posts from this blog

A Valuable FMCG Company for Long Term Investment

A household name for FMCG products in India, the company has strong visibility in growth and earnings in India’s long runway story - As investors shift to safe havens, the Stock has rallied significantly in past few weeks. The question is, if this ‘driver of consumption’ valuable at this Price? Revenue for FY20 stood at INR 397.8 Billion recording a 1.20% Y-O-Y growth with an Operating Profit Margin of 22.27%. For Q4 FY20, revenues were at INR 92.11 Billion with a negative growth Year-on-Year and an Operating Profit Margin of 19.85%. In the past 5 years, revenue has compounded by about 4.60%. The OPM improved from 15.2% in FY 2015 to 22.2% in FY 2020. The Company attributed the Q4 decline due to supply chain disruption during the first phase of the Lockdown. The Lockdown is expected to affect the production and demand destruction till September 2020 and then show improvements. Stock Returns Percentage 1 Year 23.82% 3 Years 28.00% ...

SBI Card IPO - SBI Cards & Payment Services Limited IPO

Objects of the SBI Card IPO: a) The Offer for Sale: The object of the Offer for Sale is to allow the Selling Shareholders to sell an aggregate value up to Rs.8000 Crores of shares held by them.   b) Fresh Issue( 500 Crores )  The net proceeds of the Fresh Issue are proposed to be utilized for augmenting the capital base to meet the future capital requirements. Overview of SBI Card (a) They are the second-largest credit card issuer in India, with an  18.0%  market share of the Indian credit card market in terms of the number of credit cards outstanding as of September 30, 2019. SBI Card is a subsidiary of State Bank of India. (b)  They offer an extensive credit card portfolio to individual cardholders and corporate clients which includes lifestyle, rewards, travel and fuel, shopping, banking partnership cards and corporate cards covering all major cardholder segments in terms of income profiles and lifestyles. (c)  SBI Card has ...

DMART : 3rd Quarterly Results